CARDIORESPIRATORY DISEASE
- Includes: cardiac or pulmonary disorders (e.g., COPD, asthma, cystic fibrosis, conditions affecting ability to clear airway secretions)2
It’s time to rethink defense against RSV.
mRESVIA – now available to help safeguard your patients against LRTD caused by RSV
mRESVIA® (Respiratory Syncytial Virus [RSV] mRNA Vaccine) is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults 60 years of age and older, and adults 18 through 59 years of age who are at increased risk for LRTD caused by RSV.1
Why choose to vaccinate against RSV?
RSV is a common respiratory virus that infects almost all Canadians by the age of 2 years and causes recurrent infections throughout their life.2 Most adults experience symptoms similar to a common cold. However, for some individuals – particularly those with increasing age – RSV infection can lead to severe disease.3
RSV activity peaks during the fall and winter months and can have serious complications for older adults and adults with certain medical conditions.4,5
The National Advisory Committee on Immunization (NACI) strongly recommends vaccination against RSV for all adults 75 years and over, and for certain adults at high risk of severe RSV disease.2
Identifying patients at increased risk for severe RSV disease2
While RSV generally presents as a mild illness, some populations are at increased risk for severe RSV disease and outcomes.2,6 And for those also living with chronic comorbidities, the risk may be even higher.2
Clinically significant chronic health conditions identified by NACI that are associated with increased risk of severe RSV disease2
METABOLIC DISEASES
- Includes: Class 3 obesity (BMI ≥40 kg/m2); diabetes mellitus; other metabolic diseases2
IMMUNOCOMPROMISED
- Includes: moderate and severe primary immunodeficiency diseases; solid organ or blood stem cell transplant; immunosuppressing medications (e.g., corticosteroids)2,7
NEUROLOGIC CONDITIONS
- Includes: neuromuscular, neurovascular, neurodegenerative [e.g., dementia], neurodevelopmental conditions; seizure disorders2†
OTHER DISEASES
- Includes: chronic kidney disease; chronic liver disease2
Adapted from NACI (2025).2
BMI=body mass index; COPD=chronic obstructive pulmonary disease; LRTD=lower respiratory tract disease; NACI=National Advisory Committee on Immunization; RSV-LRTD=respiratory syncytial virus-associated lower respiratory tract disease.
* With domestic and imported parts.
† Excludes migraines and psychiatric conditions without neurological conditions.2
NACI guidance on RSV vaccines for older adults and those at high risk for severe disease2‡
STRONG recommendation2
Vaccine immunization programs should include:
All adults aged ≥75 years
Adults aged 65–74 years who are at increased risk for severe disease
Adults aged ≥18 years who:
- are residents of nursing homes and other chronic care facilities
- have had a lung transplant
- have had a hematopoietic stem cell transplant (in the previous two years or who remain on immunosuppression)
- are on home oxygen or require chronic oxygen therapy regardless of living at home or elsewhere
- are receiving dialysis
Considerations:
There is still uncertainty about the total duration of protection and the need for and timing of any potential booster doses with any of the authorized adult RSV vaccine products. Therefore, a single dose is currently recommended.
DISCRETIONARY recommendation2
Recommendation for individual decision-making (i.e., clinicians wishing to advise individual patients about immunization against RSV):
RSV vaccines may be considered by adults aged 18–64 years at increased risk for severe RSV disease
Considerations:
- A careful assessment of benefits vs. potential harms is warranted, as most younger adults may benefit more from vaccination at an older age or if their risk for severe RSV disease increases.
- A single dose of vaccine is currently recommended and is expected to provide protection for RSV disease for ≥3 years. For adults aged <60 years at increased risk, the currently recommended dose should be administered at a time when maximal clinical benefit is expected.
For the full statement, consult the Updated guidance on RSV vaccines for older adults and for adults at high risk of severe disease.
“Available evidence shows that all three RSV vaccines trigger a strong immune response.”
− National Advisory Committee on Immunization (NACI)2
‡ Provincial/territory criteria may vary. Refer to your regional health authority for complete eligibility criteria.
RSV vaccine programs by province/territory
To view the eligibility criteria for your area, please select from the list of provinces and territories.
Important: eligibility criteria may change at undefined times. Always consult with your regional health authority for the latest information.
Select an area
Eligibility Summary
Select a province or territory to view its eligibility criteria.
We’re here to help
Get in touch with questions or for any information you may need.
Important information
Indications and clinical use:
mRESVIA® (Respiratory Syncytial Virus [RSV] mRNA Vaccine) is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults 60 years of age and older, and adults 18 through 59 years of age who are at increased risk for LRTD caused by RSV.
Pediatrics: safety and efficacy in individuals under 18 years of age have not been established. mRESVIA is not indicated for pediatric use.
Contraindications:
- Hypersensitivity to mRESVIA or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
- Children less than 2 years of age due to an increased risk of severe and/or life-threatening RSV-enhanced respiratory disease reported in infants during a pediatric study. The risk of RSV-enhanced respiratory disease is not applicable to adults.
Relevant warnings and precautions:
- Postpone vaccination in individuals with an acute severe febrile illness
- Syncope
- Anaphylaxis
- Use in individuals with thrombocytopenia or coagulation disorders
- mRESVIA may not protect all vaccine recipients
- Use in immunocompromised individuals
- Not recommended during pregnancy
- Use in breastfeeding individuals
For more information:
Please consult the Product Monograph for important information relating to adverse reactions, drug interactions, and dosing information, which has not been discussed in this piece. The Product Monograph is also available by calling us at 1-866-MODERNA (1-866-663-3762).
References
- mRESVIA Product Monograph. Moderna Biopharma Canada Corp.
- Public Health Agency of Canada. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI): updated guidance on respiratory syncytial virus (RSV) vaccines for older adults and for adults at high risk of severe RSV disease. Publication date: April 2026.
- Government of Canada. Respiratory syncytial virus (RSV) vaccines: Canadian Immunization Guide. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html#a2/. Accessed June 10, 2026.
- National Advisory Committee on Immunization (NACI). Summary of NACI statement of April 10, 2026: Updated guidance on respiratory syncytial virus (RSV) vaccines for older adults and for adults at high risk of severe RSV disease. Available at: https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-updated-guidance-respiratory-syncytial-virus-vaccines-older-adults-high-risk-severe-rsv-disease.html. Accessed June 2, 2026.
- Public Health Agency of Canada (PHAC). Respiratory syncytial virus (RSV): For health professionals. Available at: https://www.canada.ca/en/public-health/services/diseases/respiratory-syncytial-virus-rsv/health-professionals.html. Accessed June 2, 2026.
- Government of Canada. Respiratory syncytial virus (RSV): Spread, prevention and risks. Available at: https://www.canada.ca/en/public-health/services/diseases/respiratory-syncytial-virus-rsv/prevention-risks.html. Accessed June 10, 2026.
- Government of Canada. COVID-19 vaccines: Canadian Immunization Guide. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html#a6.4. Accessed June 10, 2026.
- Government of Canada. Provincial and territorial routine vaccination programs for healthy, previously immunized adults. Available at: https://www.canada.ca/en/public-health/services/immunization-vaccines/routine-vaccination-healthy-previously-immunized-adult.html. Accessed June 6, 2026.
- Primary Care Alberta. Respiratory syncytial virus (RSV) vaccine. Available at: https://myhealth.alberta.ca/Topic/Immunization/pages/rsv-vaccine.aspx. Accessed June 6, 2026.
- Healthlink BC. Respiratory syncytial virus (RSV) vaccine. Available at: https://www.healthlinkbc.ca/healthlinkbc-files/respiratory-syncytial-virus-rsv-vaccine. Accessed June 6, 2026.
- Government of Manitoba. Eligibility criteria for Manitoba’s publicly funded immunization program. Available at: https://www.gov.mb.ca/health/publichealth/cdc/vaccineeligibility.html#RSV. Accessed June 6, 2026.
- Government of New Brunswick. Respiratory syncytial virus (RSV) vaccine. Available at: https://www2.gnb.ca/content/gnb/en/departments/health/DrugPlans/TheNewBrunswickPrescriptionDrugProgram/publichealthplan/rsv-vaccine.html. Accessed June 6, 2026.
- Government of Newfoundland and Labrador. Provincial government expanding access to RSV vaccines through budget 2026. Available at: https://www.gov.nl.ca/releases/2026/health/0427n01/. Accessed June 6, 2026.
- Nova Scotia Health. Province expanding access to RSV protection for infants, older Nova Scotians. Available at: https://news.novascotia.ca/en/2025/09/10/province-expanding-access-rsv-protection-infants-older-nova-scotians. Accessed June 6, 2026.
- Government of Northwest Territories. Health and Social Services: NWT immunization schedule. Available at: https://www.hss.gov.nt.ca/en/services/immunization-vaccination/nwt-immunization-schedule. Accessed June 6, 2026.
- Government of Nunavut. RSV prevention program in Nunavut. Available at: https://www.gov.nu.ca/en/newsroom/rsv-prevention-program-nunavut-2024-12-13-0. Accessed June 6, 2026.
- Public Health Ontario. Respiratory Syncytial Virus (RSV). Available at: https://www.publichealthontario.ca/en/Diseases-and-Conditions/Infectious-Diseases/Respiratory-Diseases/RSV. Accessed June 6, 2026.
- Prince Edward Island Chief Public Health Office Policy. RSV vaccine for older adults: immunization policy. Available at: https://src.healthpei.ca/sites/src.healthpei.ca/files/nursingeducation/RSV_Vaccine_for_Older_Adults_Immunization_Policy.pdf. Accessed June 6, 2026.
- Government of Quebec. Immunization against respiratory syncytial virus (RSV) infections. Available at: https://www.quebec.ca/en/health/advice-and-prevention/vaccination/immunization-against-respiratory-syncytial-rsv-infections. Accessed June 6, 2026.
- Saskatchewan Ministry of Health. Respiratory syncytial virus (RSV) vaccines. Available at: https://medsask.usask.ca/sites/medsask/files/2024-10/RSV_Vaccines_FactSheet.pdf. Accessed June 6, 2026.
- Yukon Immunize. Immunization schedules. Available at: https://yukonimmunization.ca/get-immunized/immunization-schedules. Accessed June 6, 2026.
Stay up to date with Moderna Canada
Sign up if you are interested in being contacted by Moderna to receive scientific, medical and promotional information, including invitations to medical education events or webinars and information on opportunities for scientific, medical and promotional engagements.
* Required.